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Abstract
Background The minimally invasive esophagectomy (MIE) is widely being implemented for esophageal cancer in
order to reduce morbidity and improve quality of life. Non-randomized studies investigating the mid-term quality of
life after MIE show conflicting results at 1-year follow-up. Therefore, the aim of this study is to determine whether
MIE has a continuing better mid-term 1-year quality of life than open esophagectomy (OE) indicating both a faster
recovery and less procedure-related symptoms.
Methods A one-year follow-up analysis of the quality of life was conducted for patients participating in the randomized
trial in which MIE was compared with OE. Late complications as symptomatic stenosis of anastomosis are also reported.
Results Quality of life at 1 year was better in theMIE group than in the OE group for the physical component summary
SF36 [50 (6; 48–53) versus 45 (9; 42–48)p .003]; global healthC30 [79 (10; 76–83) versus 67 (21; 60–75)p .004]; and pain
OES18 module [6 (9; 2–8) versus 16 (16; 10–22) p .001], respectively. Twenty six patients (44 %) in the MIE and 22
patients (39 %) in the OE group were diagnosed and treated for symptomatic stenosis of the anastomosis.
Conclusions This first randomized trial shows that MIE is associated with a better mid-term one-year quality of life
compared to OE.
Introduction
Esophagectomy with lymphadenectomy after neoadjuvant
chemoradiotherapy or chemotherapy is regarded as the
only curative option for patients with resectable esophageal
cancer [1–3]. This operative procedure has a high incidence
of postoperative complications, especially pulmonary
infections and is also associated with an impaired quality of
life [4]. Minimally invasive procedures are increasingly
implemented for reducing such complications and
improving postoperative quality of life.
To date, the short-term results of only one randomized
trial have been published. This multicenter, randomized
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trial provides evidence for certain short-term benefits of the
minimally invasive approach for patients with resectable
esophageal cancer. It reported significantly less pulmonary
infections after the minimally invasive esophagectomy
(MIE) as well as better pain scores, less blood loss and a
shorter hospital stay. Importantly, this trial showed a better
short-term quality of life at 6 weeks after surgery for the
patients who underwent a MIE procedure [5].
The quality of life after open transthoracic esophagec-
tomy usually improves within 1 year [6]. However, studies
investigating the mid-term quality of life after MIE show
conflicting results at 1-year follow-up [7–13]. Furthermore,
these results are based on analysis of patient series and
non-randomized study design.
Therefore, a 1-year follow-up analysis of the quality of
life was conducted for patients participating in the ran-
domized trial in which MIE was compared with open
esophagectomy (OE) [5, 14]. We investigated if MIE has a
continuing better mid-term 1 year quality of life than OE
indicating both a faster recovery and less procedure-related
symptoms. Additionally, late complications and 1-year
follow-up survival data are also reported.
Methods
Study design and patients
This study at 1-year follow-up is an analysis of a multi-
center, randomized trial which was performed between
June 1, 2009 and March 31, 2011 at five centers: two in
Amsterdam (Netherlands), and one in Nijmegen (Nether-
lands), Girona (Spain), and Milan (Italy) [5]. Eligible
participants had resectable esophageal cancer
(cT1–3,N0–1, M0), histologically proven adenocarcinoma,
squamous cell carcinoma, or undifferentiated carcinoma of
the intrathoracic esophagus and gastro-esophageal junc-
tion. Patients were aged 18–75 years and had a WHO
performance status of two or less. We excluded patients
with cervical esophageal cancer or another malignancy.
For quality assurance, the principal investigator visited
all centers interested in trial participation. Minimally
invasive esophagectomies were observed in person by the
principal investigator. Both procedures were done by sur-
geons experienced in open esophageal resection, and with
extensive experience in minimally invasive procedures,
who had done at least ten MIE. Only hospitals with more
than 30 esophagectomies per year participated and their
medical ethics boards approved the trial. Diagnosis and
staging was established before neoadjuvant treatment by
esophagoscopy and biopsies; CT scans of the neck, thorax,
and abdomen; and endo-ultrasonography.
Surgeons at the outpatient clinic informed eligible
patients of the treatment regimen. Written informed con-
sent was obtained from included patients. We used a
computer-generated randomisation sequence to randomly
assign patients, in a 1:1 ratio, to undergo either open or
minimally invasive esophagectomy. Randomisation was
stratified by study center. All participating centers com-
piled an exclusion list to analyse the quality of the ran-
domisation rate. Patients, and investigators undertaking
interventions, assessing outcomes, and analysing data were
not masked to group assignment.
Operative procedure
Patients in both groups received identical pre-and postop-
erative treatment. For most patients, neoadjuvant treatment
consisted of weekly administrations of 50 mg/m2 pacli-
taxel plus carboplatin (Calvert’s formula for dosing; area
under the concentration–time curve 2 for 5 weeks) and
concurrent radiotherapy (41,4 Gy in 23 fractions for 5 days
per week). After 6–8 weeks, neoadjuvant treatment was
followed by surgery by open or minimally invasive
esophagectomy.
Open esophagectomy involved a right posterolateral
thoracotomy in the lateral decubitus position with double
tracheal intubation and lung block, midline laparotomy,
and cervical or intrathoracic anastomosis. MIE was per-
formed through a right thoracoscopy in the prone position
with single-lumen tracheal intubation, upper abdominal
laparoscopy, and cervical incision. For patients undergoing
MIE with an intrathoracic anastomosis, a bronchus blocker
was placed in the right bronchus to help with one-lung
ventilation during anastomosis.
Both procedures included a two-field esophageal resec-
tion with 3–4 cm wide gastric tube formation followed by a
cervical or intrathoracic anastomosis. Further details of the
surgical techniques for open and MIE have been published
elsewhere [15].
In the first 3 days after surgery, patients received
epidural analgesia. If epidural analgesia was unsuccessful,
patient-controlled analgesia with intravenous opioids was
given. Enteral feeding was started on day 1 after surgery
through a percutaneous jejunostomy catheter.
Study endpoints
The primary short-term endpoint of the study was postop-
erative pulmonary infection, defined as clinical manifesta-
tion of pneumonia or bronchopneumonia confirmed by
thoracic radiographs or CT scan (assessed by independent
radiologists) and a positive sputum culture, within the first
2 weeks of surgery and during the whole stay in hospital.
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Secondary short-term endpoints included among others
postoperative complications other than pulmonary infec-
tions (e.g., anastomotic leakage, vocal cord paralysis con-
firmed by laryngoscopy), quality of life [assessed by short
form 36 (SF 36) Health Survey (version 2) and European
Organization for Research and Treatment of Cancer
(EORTC) quality of life questionnaires C30 and OES18
module].
Mid-term secondary endpoints included quality of life at
1 year (assessed by SF 36 and EORTC C30 and OES18
module), incidence of late complications (e.g., anastomotic
stenosis) and overall and disease-free survival. Data were
collected prospectively during outpatient visits by paper
questionnaires. Radiological and/or endoscopic assessment
(for recurrence or metastasis) was performed only by
indication if the history and physical examination of the
patient lead to suspicion.
Statistical analysis
We used Power and Precision (version 2) for sample size
calculation for the short-term study. Previous data indi-
cated a 28 % difference in pulmonary infections between
minimally invasive (29 %) [7, 15–18] and open (57 %)
esophagectomy [19]. To show a difference of this magni-
tude, two groups of 48 patients would be needed (a 0.05, b
0.80). With an estimation that about 20 % of the eligible
patients might not undergo the allocated intervention (e.g.,
due to metastases during neoadjuvant treatment or unre-
sectable tumors), we enrolled 60 patients per group. We
expressed data as median and range for continuous vari-
ables, or mean and SDs when appropriate. We expressed
distributions of dichotomous data in percentages. When
appropriate, we compared groups with an independent
samples t test, otherwise a Mann–Whitney U test, or v2 test.
We calculated relative risk (RR) for the primary endpoint
with 95 % CIs. Data were analysed according to the




We randomly assigned 115 of 144 eligible patients to
receive either OE or MIE. Four crossovers occurred: two
patients assigned to the OE group underwent MIE, and two
assigned to MIE developed a WHO-ECOG score of 3 during
neoadjuvant treatment and were treated by transhiatal
esophagectomy. Eight patients did not undergo a resection
(Fig. 1); we included these patients in the analysis of the
allocated group according to the intention-to-treat principle.
Fifty-six patients were analysed in the OE group and 59 in
the MIE group. The demographic and clinical characteristics
of the two groups were similar at baseline (Table 1). The
short-term results are reported elsewhere [5].
Quality of life
Quality of life questionnaires were obtained at 1 year
postoperatively. A response compliance of 82 % by
patients was obtained. Under the non-responders were nine
patients with recurrence; these patients were equally dis-
tributed between both groups. Moreover, six patients did
not complete the questionnaires for unknown reasons, also
equally distributed between both groups.
Quality of life questionnaire results are shown in
Table 2. Overall the quality of life scores at 1 year were
better for both groups compared at 6 weeks and preoper-
atively when using the SF-36 and EORTC C-30 Global
health domain and the EORTC OES-18 domains. Impor-
tantly, there are significantly better scores after 1-year
follow-up for the MIE group as compared to the OE group.
These differences are present in three domains: physical
activity [SF36: 50 (6; 48–53) vs .45 (9; 42–48) p .003];
global health [C30: 79 (10; 76–83) vs. 67 (21; 60–75)
p .004]; and pain [OES18: 6 (9; 2–8) versus 16 (16; 10–22)
p .001].
Compared to postoperative levels, we see that after
1 year the patients in both groups improved their scores
without significant differences of improvement between
the groups (Table 3).
Late complications
Late complications observed during the first year are
depicted in Table 4.
After 1 year, 26 patients (44 %) in the MIE and 22
patients (39 %) in the OE group were diagnosed and
treated for symptomatic stenosis of the anastomosis.
Endoscopic dilatations were performed with a median
number of five dilatations [2–20]. One patient in the MIE
group was re-admitted at 2 months postoperatively because
of herniation of colon and small bowel in the thoracic
cavity, necessitating reposition of viable bowels through
median laparotomy.
Six weeks postoperatively, eight patients in the OE
group and one patient in the MIO group suffered from
unilateral vocal cord paralysis. One patient in the OE group
had bilateral vocal cord paralysis versus none in the MIE
group. After 1 year, three patients in the OE group
recovered from the vocal cord paralysis versus 0 (none) in
the MIE group. The patient with bilateral vocal cord
paralysis regained function of one of the vocal cords;
consequently his tracheotomy could be closed.
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Recurrence, distant metastasis, and survival
Data about local recurrence and distant metastases are
shown in Table 5. Thirty-two patients died during the first
year, 18 (32 %) in the OE group and 14 (23 %) in the MIE
group (p = 0.314). Death was related principally to distant
metastases (19 patients), without significant differences
between the two groups (p = 0.167). Local recurrence was
observed in three patients in the OE group (p = 0.072).
Discussion
In this trial, MIE resulted in a better mid-term 1-year
quality of life for the physical component summary of the
SF-36 questionnaire, EORTC C30 global health domain
and OES 18 pain domain compared to open esophagec-
tomy. In addition, there were no differences in survival and
late complications at 1 year between the groups.
The impact of the surgical procedure is apparently of
influence even after 1 year. The better physical domains of
the SF-36 and pain of the OES 18 module for the MIE
group indicate fewer limitations for the patients probably
due to less surgical trauma by the smaller incisions which
are used for MIE. Post-thoracotomy-related pain is well
known and widely reported [20, 21]. It is probably a
combination of intercostal nerve damage and myofascial
pain [22]. It has been reported that up to 50 % of patients
describe post-thoracotomy pain 1 year after the procedure
[23]. A recent study on the type of thoracotomy found an
inverse relationship between the incision length and post-
thoracotomy pain [24]. With MIE both incision length and
myofascial damage is limited. This could explain the better
outcome at 1 year after MIE. In addition, the abdominal
incision is also smaller in MIE compared to OE. However,
the influence of abdominal wall pain after laparotomy at
1 year is probably marginal compared to the influence of
post-thoracotomy pain on quality of life. Therefore, we
Fig. 1 Trial profile MIE minimally invasive esophagectomy, WHO-ECOG World Health Organization- Eastern Cooperative Oncology Group,
QoL quality of life. Analysis: intention-to-treat
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found the difference specifically in the chest pain domain
of the EORTC OES18 and it did not appear in the overall
bodily pain domain of the SF-36. The experience of pain
and dysfunction in the right shoulder and protracted pain
in the thoracotomy scar is frequent and relevant as these
effects were observable in the clinical differences at the
outpatient clinic. As the scores in the OES-18 have
shown, the post-thoracotomy pain syndrome had a nega-
tive influence upon daily activities in one third of
patients.
Postoperative health-related quality of life is impaired in
patients with esophageal cancer in comparison to preop-
erative levels [8, 9] and to that of healthy reference pop-
ulations [25–27]. The recovery after esophagectomy to
preoperative levels was present for both groups at 1 year.







Male 46 (82 %) 43 (73 %)
Female 10 (18 %) 16 (27 %)
Age (years)* 62 (42–75) 62 (34–75)
BMI (kg/m2) 24 (3.7) 25 (3.6)
ASA classification
1 15 (27 %) 10 (17 %)
2 32 (57 %) 34 (58 %)
3 8 (14 %) 14 (24 %)
4 1 (2 %) 1 (2 %)
Type of carcinoma
Adenocarcinoma 36 (64 %) 35 (59 %)
Squamous cell 19 (34 %) 24 (41 %)
carcinoma 1 (2 %) 0 (0 %)
Other neoadjuvant treatment
Chemoradiotherapy 52 (93 %) 54 (92 %)
Chemotherapy alone 4 (7 %) 5 (8 %)
Location of tumor
Upper third 3 (5 %) 1 (2 %)
Middle third 22 (39 %) 26 (44 %)
Lower third or gastro-esophageal junction 31 (55 %) 32 (54 %)
Level of anastomosis
Cervical 37 (66 %) 38 (64 %)
Thoracic 15 (27 %) 17 (29 %)
Total lymph nodes retrieved*
Resection margin} 21 (7–47) 20 (3–44)
R0 47 (84 %) 54 (92 %)
R1 5 (9 %) 1 (2 %)
pStage§
0 0 (0 %) 1 (2 %)
I 4 (7 %) 4 (7 %)
IIa 16 (29 %) 17 (29 %)
IIb 6 (11 %) 9 (15 %)
III 14 (25 %) 11 (19 %)
IV 5 (9 %) 4 (7 %)
No residual tumor of lymph-node
metastasis
7 (13 %) 9 (15 %)
Data are n (%), median (range), and mean (SD)
OE open esophagectomy, MIE minimally invasive esophagectomy,
BMI body-mass index, ASA American Association of Anesthesiologists
* Skewed distribution, Mann–Whitney test applied
 Normal distribution, independent samples t test applied
 American Joint Committee on cancer site classification of thoracic
and abdominal esophagus
} efined as[1 mm from a resection marge
§ Staging based on the American Joint Committee on cancer, 6th edn;
four patients in each group did not undergo resection due to metastasis
or irresectability
Table 2 Quality of life domains
OE ( 31) MIE (33) p value
SF 36
Mental component summary
Preoperatively 45 (9; 43-48) 46 (12; 43–49) .955
6 weeks 45 (11; 40–50) 46 (10; 41–50) .806
1 year 50 (10; 47–53) 53 (10; 49–56) .317
Physical component summary
Preoperatively 43 (9; 40–46) 46 (8; 44–48) .072
6 weeks 36 (6; 34–39) 42 (8; 39–46) .007
1 year 45 (9; 42–48) 50 (6; 48–53) .003
EORTC C30
Global health
Preoperatively 63 (23; 56–70) 66 (22; 60–72) .631
6 weeks 51 (21; 44–58) 61 (18; 56–67) .020
1 year 67 (21; 60–75) 79 (10; 76–83) .042
EORTC OES 18
Pain
Preoperatively 23 (17–22, 22–30) 17 (24; 11–24) .187
6 weeks 19 (13–21, 21–26) 8 (11; 5–11) .002
1 year 16 (16; 10–22) 6 (9; 3–10) .003
Talking
Preoperatively 12 (25; 4–19) 10 (23; 4–17) .745
6 weeks 37 (39; 25–49) 18 (26; 10–26) .008
1 year 10 (21; 3–18) 5 (14; 0–11) .288
Only the one-year QOL differences that were significant are in bold
Data are mean (SD, 95 %CI)
OE open esophagectomy, MIE minimally invasive esophagectomy,
EORTC European Organization for Research and Treatment of
Cancer Quality of Life Questionnaires, SF 36 Short Form 36 Health
Survey (version 2)
Measures general aspects of health; scores range from 0 to 100, with
higher scores representing better well-being
 Assesses several aspects of esophageal function; scores range from
0 to 100, with lower scores indicating better function
1990 World J Surg (2015) 39:1986–1993
123
Quality of life data after MIE is limited. Parameswaran
et al. studied 97 patients undergoing OE, laparoscopic-as-
sisted esophagectomy (LAE), or MIE for high-grade dys-
plasia or cancer [9]. Patients completed validated
questionnaires before, after 6 weeks, at three and 6 months
after surgery. Following surgery, the fatigue levels
increased dramatically and activity levels reduced in all
groups after 6 weeks. These gradually recovered to base-
line levels following MIE and LAE within 6 months, but
the scores regarding ability to perform activities of daily
living and most indicators of fatigue had not returned to
baseline levels in the OE group. Although the studied
questionnaires in the above mentioned study differs from
our protocol and is of non-randomized design, nonetheless
it is clear that the trend is comparable. In our study, we also
see a drop at 6 weeks after surgery and even better results
than baseline after 1 year. At 6 weeks postoperatively it
was clear that the difference between the groups was
clinically significant as the minimally invasive group had
significant fewer pulmonary complications, probably due
to other factors such as less surgical trauma and less pain
[5]. At 1 year the same differences were present and thus
also clinically significant. In our opinion, all differences
between the groups in the specific domains result in a
clinically important difference, which is best understood
for the pain domain due to post-thoracotomy pain. The
improvement of quality of life after 1 year was equal for
both groups compared to 6 weeks postoperatively.
Furthermore, in this trial, overall survival and disease-
free survival rates after 1 year were not different between
the groups. This data are in concordance with recent lit-
erature of patients treated by neoadjuvant therapy followed
by esophageal resection [2, 3]. Local recurrence and distal
metastases were also not different between the groups and
comparable with other reports [3, 28]. However, reliable
survival analysis is usually performed at 5 years postop-
eratively. This will be reported in the future.
The rate of late complications—as defined between the
discharge and 1-year follow-up—does not differ between
the two groups. Almost 40 % of the patients necessitated
dilatations because of symptomatic benign stenosis of the
gastric tube anastomosis. The median average of dilatations
was five per patient. This outcome corresponds with other
prospective studies [29, 30].
Interesting is the recovery during the first postoperative
year of vocal cord paralysis in patients of the OE group. At
6 weeks after operation, eight patients in the OE group
versus one patient in the MIE group suffered from vocal
cord paralysis, whereas at 1-year three patients of the OE
Table 3 Improvement (delta) of Quality of life in time
OE MIE p value
SF36
Mental component summary 10 (0.499) 10 (0.514) 0.546
Physical component summary 10 (0.327) 9 (0.406) 0.465
EORTC C30
Global health 14 (0.518) 16 (0.498) 0.080
EORTC OES18
Pain -7 (0.366) 0 (-0.041) 0.065
Talking -28 (0.256) -18 (-0.083) 0.091
Data are mean difference between 6 weeks postoperatively and one year postoperatively (correlation coefficient)
OE open esophagectomy, MIE minimally invasive esophagectomy, EORTC European Organization for Research and Treatment of Cancer
Quality of Life Questionnaires, SF 36 short form 36 health survey (version 2)
Table 4 Late complications one year postoperatively
OE (56) MIE (59) p value
Stenosis anastomosis 22 (39 %) 26 (44 %) 0.603
Intrathoracic herniation 1 (2 %) 0 (0 %) 0.303
Vocal cord paralysis 4 (7 %) 1 (2 %) 0.152
Data are n (%)
OE open esophagectomy, MIE minimally invasive esophagectomy
Table 5 Overall and disease-free survival at one year
OE (56) MIE (59) p value
Overall survival 38 (68 %) 45 (76 %) 0.314
Disease-free survival 33 (59 %) 41 (69 %) 0.237
Causes of death 18 (32 %) 14 (24 %) 0.314
Metastases 12 (21 %) 7 (12 %) 0.167
Recurrence 3 (5 %) 0 (0 %) 0.072
In hospital mortality 1 (2 %) 2 (3 %) 0.590
Irresectable tumor 1 (2 %) 3 (5 %) 0.335
Other causes 1 (2 %) 2 (3 %) 0.590
Data are n (%)
OE open esophagectomy, MIE minimally invasive esophagectomy
World J Surg (2015) 39:1986–1993 1991
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group had recovered the vocal function. Probably, neuro-
praxy of the nerve explains this recovery. In accordance
with this recovery, scores on the domain ‘talking’ in the
EORTC OES18 reveal no more difference between the
groups 1 year after surgery.
This study has some limitations. This trial was powered
for short-term pulmonary infections and not for mid-term
quality of life. However, considering the impaired physical
domains of the quality of life which is probably related to
post-thoracotomy pain it is likely that this difference with
the MIE group would still be present. Other trials, powered
for quality of life, are however needed to confirm our
results. In addition, the quality of life questionnaires at
1 year was not completed by all patients (82 % comple-
tion). Some patients with cancer recurrence did not com-
plete the questionnaires. Given their equal distribution in
both groups the influence of the non-responders is small in
the final outcome.
In conclusion, this first randomized trial shows that MIE
for esophageal cancer is associated with a better mid-term
1-year quality of life compared to open esophagectomy.
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